2025-08-08 20:09:32
Latest Post
Zydus receives final approval from USFDA for Prucalopride Tablets, 1 mg and 2 mg
Central Bank of India Launches Pioneering TReDS Insurance Policy In Strategic Partnership With TATA AIG
Bangur Concrete Launches First RMC Plant in Karnataka, Enters South India Market
Gateway Distriparks Signs Exclusive Container Train Operations Agreement for MMLP, Ankleshwar
RBI grants NBFC license to Equirus Group
Stock Report
Aarey Drugs and Pharmaceuticals Ltd Q3FY23 PAT slides to Rs. 49.45 lakhs
Posted On : 2023-02-08 18:23:20( TIMEZONE : IST )
AAREY DRUGS & PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 62.9494 crores during the period ended December 31, 2022 as compared to Rs. 75.3201 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 0.4945 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 2.1192 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 0.19 for the period ended December 31, 2022 as compared to Rs. 0.83 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹62.9494 crs | ₹75.3201 crs |  -16.42% |
| Net Profit | ₹0.4945 crs | ₹2.1192 crs | -76.67% |
| EPS | ₹0.19 | ₹0.83 | -77.11% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.62.9494 crores during the period ended December 31, 2022 as compared to Rs.140.3944 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.0.4945 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.1.9480 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.0.19 for the period ended December 31, 2022 as compared to Rs.0.77 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹62.9494 crs | ₹140.3944 crs | -55.16% |
| Net Profit | ₹0.4945 crs | ₹1.9480 crs | -74.61% |
| EPS | ₹0.19 | ₹0.77 | -75.32% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.257.9646 crores during the 9 Months period ended December 31, 2022 as compared to Rs.374.0469 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.3.4139 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.7.3001 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.1.34 for the 9 Months period ended December 31, 2022 as compared to Rs.2.88 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹257.9646 crs | ₹374.0469 crs | -31.03% |
| Net Profit | ₹3.4139 crs | ₹7.3001 crs | -53.23% |
| EPS | ₹1.34 | ₹2.88 | -53.47% |
Shares of AAREY DRUGS & PHARMACEUTICALS LTD. was last trading in BSE at Rs. 35.05 as compared to the previous close of Rs. 34.30. The total number of shares traded during the day was 17275 in over 157 trades.
The stock hit an intraday high of Rs. 35.20 and intraday low of 34.05. The net turnover during the day was Rs. 601179.00.
